Management of advanced colorectal cancer, part 2-Reference-Cited by-同舟云学术

Management of advanced colorectal cancer, part 2

Published:2013-03-01 Issue:6 Volume:70 Page:491-506
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Cersosimo Robert J.¹

Affiliation:

1. School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, and Pharmacy Consultant, Veterans Affairs Medical Center, Boston

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/70/6/491/28456687/ajhp0491.pdf

Reference84 articles.

1. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study;Fuchs;J Clin Oncol,2007

2. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer;Sobrero;Oncology,2009

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Chemotherapy on Fusobacterium nucleatum Abundance in Colorectal Cancer Patients: A Study on Relapsing Patients;Indian Journal of Microbiology;2024-04-22

2. The alterations of microbiota and pathological conditions in the gut of patients with colorectal cancer undergoing chemotherapy;Anaerobe;2021-04

3. Regulation of Wnt receptor activity: Implications for therapeutic development in colon cancer;Journal of Biological Chemistry;2021-01

4. Upregulation of adipocyte enhancer‐binding protein 1 in endothelial cells promotes tumor angiogenesis in colorectal cancer;Cancer Science;2020-04-11

5. miR‑361 enhances sensitivity to 5‑fluorouracil by targeting the FOXM1‑ABCC5/10 signaling pathway in colorectal cancer;Oncology Letters;2019-08-14